Back to Results
Hans Klingemann, MD, PhD
Meet Hans Klingemann, MD, PhD
Title(s)
Adjunct Professor, Tufts University School of Medicine
Department + Services
Cancer Center
Clinical Focus Areas
Cellular immunotherapy
Research Focus Areas
Cellular Immunotherapy: T-cells, CAR-T and CAR NK cells, combination of antibodies and human cells, genetic engineering of human cells to make them targeted to individual tumors – use of NK cells to treat microbial infections
| Training + Education |
University of Wuerzburg Medical School, Germany; University of Marburg Medical School, Germany; Fred Hutchinson Cancer Research Center, Seattle, WA
|
| Board Certifications |
Hematology (Germany), Internal Medicine eligible (US) |
| NPI # |
1679677314 |
| Gender |
Male |
| Language(s) |
German |
| Accepted Insurances |
View Accepted Insurances at Tufts Medical Center
|
1992, Fellow in Clinical Immunology (FCACB) – Canada
1984-1986, German Cancer Society fellowship
1977, Wolf Boas Award of the German Society for GI disease for the best doctoral thesis
Yan Y, Steinherz P, Klingemann H-G, Denning D, Childs BH, McGuirk J, O’Reilly RJ. Antileukemia activity of a natural killer cell line against human leukemia. Clin. Cancer Res. 1998; 4:2859-68.
Tam YK, Miyagawa B, Ho VC, Klingemann H-G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 1999; 8:281-290
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H-G. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma – a phase I trial. Cytotherapy 2009; 10:625-32
Uherek C, Tonn T, Herrmann B, Becker S, Schnierle B, Klingemann H-G, Wels W. Retargeting of NK-cell cytolytic activity to ErbB2 expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100:1265-73
Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H-G. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 2009; 33: 1255-59
Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels W, Klingemann H. Retargeting NK-92 by means of CD19-and CD20 specific chimeric antigen receptors compares favorably with antibody dependent cellular cytotoxicity. OncoImmunology, 2013; 10: e26527
Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein A, Sprague K, Miller K, Comenzo R, Kewalrami T, Neng Y, Van Etten RA, McKenna D. Autologous stem cell transplant recipients tolerate haploidentical reated-donor killer cell enriched infusions. Transfusion. 2013; 53:412-8
Dr. Klingemann is currently VP of Research and Development at NantKwest (NASDAQ: NK), the company he founded in 2002 as ZelleRx based on the core technology of NK-92, developed when he was at the University of British Columbia. He is the former Director of the Bone Marrow and Stem Cell Transplant Program at Boston’s Tufts Medical Center and the Cancer Center’s Hematological Malignancies Program. Before coming to Boston, Dr. Klingemann served as Director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center in Chicago, and was the founding Director of the Sramek Center for Cell Engineering, the first center of its kind in Illinois. He has worked as physician, scientist, educator, and administrator in leadership positions for more than 25 years at various academic medical centers in Europe, Canada and the United States and has authored over 180 scientific and medical papers.
